Safety of Rapid-Acting Insulin Analogs Versus Regular Human Insulin

被引:10
|
作者
Kitabchi, Abbas E. [1 ]
Gosmanov, Aidar R. [1 ]
机构
[1] Univ Tennessee, Hlth Sci Ctr, Div Endocrinol Diabet & Metab, Memphis, TN 38163 USA
来源
AMERICAN JOURNAL OF THE MEDICAL SCIENCES | 2012年 / 344卷 / 02期
关键词
Diabetes; Hypoglycemia; Insulin; Pharmacokinetics; Pharmacodynamics; IMPAIRED GLUCOSE-TOLERANCE; TYPE-1 DIABETIC PREGNANCY; GLYCEMIC CONTROL; SOLUBLE INSULIN; RISK-FACTOR; ASPART; HYPOGLYCEMIA; MANAGEMENT; GLULISINE; EFFICACY;
D O I
10.1097/MAJ.0b013e3182449ff9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Insulin is the most effective treatment for both type 1 and type 2 diabetes mellitus. There are several differences in the safety profiles of each type of insulin, including rapid-acting insulin analogs and regular human insulin. The pharmacokinetic and pharmacodynamic properties of those insulin types also differ, as do their safety parameters. Treatment with rapid-acting analogs results in less hypoglycemia overall and decreased frequency of both severe and nocturnal hypoglycemia. In addition, the more rapid onset and shorter duration of action of rapid-acting insulin analogs are associated with greater control of postprandial glucose than regular human insulin. This review will describe the similarities and differences between the safety profiles of rapid-acting insulin analogs.
引用
收藏
页码:136 / 141
页数:6
相关论文
共 50 条
  • [21] Evaluation of blood glucose changes with regular versus rapid-acting insulin for hyperglycaemia management in the emergency department
    Zou, Xiaoxu
    Treu, Cierra N.
    Laub, Jessica
    Mendoza, Christopher
    INTERNATIONAL JOURNAL OF PHARMACY PRACTICE, 2023, 31 (05) : 534 - 539
  • [22] Rapid-acting Insulin Analogs Imitating Physiology even better and assisting the Patients
    不详
    DIABETES STOFFWECHSEL UND HERZ, 2020, 29 (05): : 313 - 313
  • [23] Comparative Pharmacokinetics and Insulin Action for Three Rapid-Acting Insulin Analogs Injected Subcutaneously With and Without Hyaluronidase
    Morrow, Linda
    Muchmore, Douglas B.
    Hompesch, Marcus
    Ludington, Elizabeth A.
    Vaughn, Daniel E.
    DIABETES CARE, 2013, 36 (02) : 273 - 275
  • [24] Comparison of the efficacy and safety of rapid-acting insulin analogs, lispro versus aspart, in the treatment of diabetes: a systematic review of randomized controlled trials
    Kapur, Rahul
    Mittra, Shivani
    Tonpe, Geetanjali
    P, P.
    Raj, Praveen
    Gudat, Uwe
    Athalye, Sandeep N.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2024, 24 (06) : 543 - 561
  • [25] Rapid-acting insulin secretagogues: a clinical need?
    Home, PD
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 1999, 107 : S115 - S119
  • [26] Usefulness of rapid-acting insulin lispro in CSII
    Yanagisawa, K
    Tuchida, KI
    Endo, M
    Masuda, H
    Makita, Z
    Koike, T
    DIABETES, 2001, 50 : A446 - A446
  • [27] Precision Dosing of Rapid-Acting Insulin Matters
    Aanstoot, Henk-Jan
    Rodriguez, Henry
    Weinzimer, Stuart
    Vint, Nan
    Koeneman, Lisette
    DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 (05) : 346 - 351
  • [28] Comparison of Hypoglycemia Safety between U-100 Human Regular Insulin and Rapid-Acting Insulin Delivered By V-Go Wearable Insulin Delivery in Type 2 Diabetes
    Mora, Pablo F.
    Sutton, David R.
    Gore, Ashwini
    Baliga, Bantwal
    Goldfaden, Rebecca F.
    Nikkel, Carla C.
    Sink, John H., II
    Adams-Huet, Beverley A.
    DIABETES, 2020, 69
  • [29] Safety Profiles Related to Dosing Errors of Rapid-Acting Insulin Analogs: A Comparative Analysis Using the EudraVigilance Database
    Popa Ilie, Ioana Rada
    Vonica-Tincu, Andreea Loredana
    Dobrea, Carmen Maximiliana
    Butuca, Anca
    Frum, Adina
    Morgovan, Claudiu
    Gligor, Felicia Gabriela
    Ghibu, Steliana
    BIOMEDICINES, 2024, 12 (10)
  • [30] ANTIOXIDATIVE PROPERTIES OF HUMAN INSULIN REFERENCE MATERIAL AND RAPID-ACTING AND LONG-ACTING INSULIN ANALOG STANDARDS
    Komosinska-Vassev, Katarzyna
    Olczyk, Pawel
    Ramos, Pawel
    Mencner, Lukasz
    Olczyk, Krystyna
    Pilawa, Barbara
    ACTA POLONIAE PHARMACEUTICA, 2018, 75 (01): : 33 - 40